$VSTM

BTIG maintained a Buy rating and $18.00 price target on Verastem (VSTM) ahead of a data presentation on October 14. The stock is currently trading at $7.80, with a Strong Buy analyst consensus. Verastem reported Q2 2026 revenue of $40.07M, exceeding expectations. The company is developing KRAS G12D inhibitor VS-7375 for various cancers, with phase 1/2 data expected soon.

H.C. Wainwright reiterated a Buy rating on Verastem (VSTM) with a $18.00 price target, citing positive clinical data for avutometinib plus defactinib in ovarian cancer. The stock trades at $7.70, with a Strong Buy consensus. Verastem reported a narrower-than-expected Q2 2026 loss and revenue exceeding forecasts, driven by product sales and a license payment. Cantor Fitzgerald also reiterated an Overweight rating.

Verastem Oncology presented data from its Phase 2 RAMP 201 trial, showing positive results for its drug combination in treating recurrent low-grade serous ovarian cancer. The combination achieved objective response rates of 22% and 18% in specific patient groups, with median progression-free survival of 13 months. The FDA approved the combination in May 2025, pending confirmatory trial results. The data was presented at the International Gynecologic Cancer Society Annual Global Meeting.

Verastem Oncology shared RAMP 201 trial data, showing avutometinib + defactinib improved ORR and PFS over conventional care in recurrent LGSOC, including KRAS-mutated and wild-type subgroups. The combo is already FDA-accelerated approved for KRAS-mutant cases, with Phase 3 RAMP 301 results as a potential catalyst for label expansion.

Verastem (VSTM) reported Q2 2026 revenue of $40.1M, including $25.1M from product sales and a $15M milestone. Net loss was $30.6M, down from $41.3M YoY. Cash position is $136.4M, with a pro forma balance of $201.4M. The company expects cash runway into 2H 2027 and LGSOC business self-sustainability by year-end. Clinical trials for VS-7375 are progressing, with Phase III plans for 2027.

Armistice Capital, LLC and Steven Boyd reported in a Schedule 13G/A that they beneficially own 7,024,000 shares of Verastem, Inc. common stock, or 7.76% of the class. The filing states the shares carry shared voting and dispositive power, with no sole voting or dispositive authority.

Verastem (VSTM) reported Q2 2026 net product revenue of $25.1M from the AVMAPKI FAKZYNJA CO-PACK launch and total revenue of $40.1M, including a $15M Secura Bio milestone. Non-GAAP adjusted net loss was $30.6M ($0.31/share). Cash and investments were $136.4M; pro forma cash $201.4M. VS-7375 Phase II trials advanced.

Verastem Oncology (Nasdaq: VSTM) reported Q2 2026 results: GAAP EPS -$0.35 and non-GAAP EPS -$0.31, with revenue of $40.1 million. Revenue rose from $2.1 million a year earlier, driven by AVMAPKI FAKZYNJA CO-PACK net product revenue of $25.1 million and a $15.0 million COPIKTRA milestone. Cash and investments were $136.4 million at June 30, 2026.

Verastem Inc (VSTM) Q2 2026 earnings call covered KRAS G12D program updates, including continued work on an Alaska partnership and exploration of PRMT5 options. Management cited a 30% ORR with 6 months durability as an FDA rule of thumb for accelerated approval, and said Q2 COPA revenue growth came from new prescribers and longer therapy duration.

Verastem, Inc. (VSTM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Delivering Novel Therapies for RAS/MAPK Pathway-Driven Cancers C O R P O R A T E P R E S E N T A T I O N A U G U S T 2 0 2 6 2 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements about, among other things, Verastem Oncology’s (the “Compan